Market access for medical devices is becoming increasingly complex. On the one hand, products are more and more technically
demanding, on the other hand, national and international regulations for approval are constantly changing. Successful market access requires not only approval but also reimbursement by the
statutory health insurances. This new book therefore aims to provide practical advice on approval and reimbursement for your market access strategies.
Order your copy from Amazon in German language.
Please contact us if you are interested in English language information on market access for medical devices.
Since 2016 and until 2019, the innovation fund has been promoting new forms of care within the German statutory health insurance system. New forms of managed care as well as the generation of
real world evidence is funded with an annual volume of 300 million euros. 225 million euros are provided for the promotion of new forms of managed
care and 75 million euros for real world evidence. The innovation committee set up at the
Federal Joint Committee (G-BA) defines the priorities and criteria for funding in so-called funding notices, carries out for expression-of-interest procedures and decides on the applications for
funding. The legal basis for the work of this innovation committee, are §§ 92a and 92b, Fifth Book of the Social Code (SGB V).
Read the full article here (in
German) or contact us for the article in English and for more information on the innovation funds and what you need to do to apply.
Regresses - Rather a perceived threat to the physician, but still a
serious obstacle for pharmaceutical companies
Whether justified or not, the fear of regresses of physicians is immense.
Whether the probability of regresses is low, the extent of damage can be great from a physician’s point of view. Many physicians are already afraid of the conspicuity itself.
Read the full article here (in German) or contact
us for the article in English and more information how to support your clients when facing regress.